Moti N. Ramgopal

Suggest Changes

Writes About:

Learn More
BACKGROUND Tenofovir alafenamide (TAF) is a novel tenofovir prodrug with improved renal and bone safety compared with TDF-containing regimens. We report the 48 week safety and efficacy of a(More)